Despite a negative reaction from investors following a major buy in the insulin delivery space, analysts still back Insulet (Nasdaq:PODD) stock to perform. Shares of PODD fell throughout today after Medtronic (NYSE:MDT) announced a $738 million acquisition of EOFlow. Korea-based EOFlow develops the EOPatch, a tubless, wearable and fully disposable insulin delivery device. Insulet represents […]
Technology
Convatec, Beta Bionics partner on iLet bionic pancreas
Convatec announced that it partnered with Beta Bionics on the launch of the iLet Bionic Pancreas for automated insulin delivery. FDA last week cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software. Convatec offers design and manufacturing services for infusion set technologies and insertion devices for insulin pump treatment. Beta […]
Medtronic to acquire wearable insulin patch maker EOFlow for $738M
Medtronic (NYSE:MDT) announced today that it entered into a set of agreements to acquire insulin delivery technology developer EOFlow. Seongnam, South Korea-based EOFlow develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow already launched its EOPatch insulin delivery system in Korea and Europe. The company submitted the insulin delivery device […]
FDA clears automated insulin pump from Beta Bionics for type 1 diabetes
The FDA announced today that it cleared the Beta Bionics iLet ACE automated insulin pump and iLet dosing decision software. FDA clearance covers the devices for people 6 years of age and older with type 1 diabetes. Combined with a compatible, FDA-cleared integrated continuous glucose monitor (iCGM), they form the iLet Bionic Pancreas. Using an […]
Study supports smart blood glucose meter from LifeScan
LifeScan today announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose […]
Dexcom touts more clinical evidence for G6 CGM in Japan
Dexcom (Nasdaq:DXCM) announced that it showcased its Dexcom G6 CGM at the 66th Annual Meeting of the Japan Diabetes Society. G6, now the previous-generation version of the company’s CGM after the launch of the G7, uses a small, wearable sensor. It also features a transmitter, continuously measuring and sending glucose levels wirelessly to a smart […]
Embecta stock rises on Q2 results, reports progress on automated insulin delivery tech
Embecta (Nasdaq:EMBC) shares ticked up today on second-quarter results that topped the consensus forecast, leading to a guidance increase. Shares of EMBC grew 2.1% to $29.52 apiece in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.1%. The Parsippany, New Jersey-based diabetes technology […]
Senseonics stock rises after hours on Street-beating Q1
Senseonics (NYSE:SENS) shares ticked up after hours on first-quarter results that topped the consensus forecast. Shares of SENS rose 1.9% at 66¢ apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.4%. The Germantown, Maryland-based company posted profits […]
Study backs Fitterfly digital therapeutic for diabetes management
New research published in JMIR Diabetes demonstrated the real-world effectiveness of the Fitterfly Diabetes digital therapeutic program. The Fitterfly Diabetes CGM digital therapeutic aims to help in the management of glycemic control for people with type 2 diabetes. Led by Shilpa Joshi, Arbinder Singal, and colleagues, the study demonstrated significant improvements in blood glucose levels and […]
Ascensia expands payment program for Senseonics Eversense E3 CGM
Ascensia Diabetes Care announced today that it expanded the Eversense PASS program for the Senseonics (NYSE:SENS) Eversense E3 CGM. Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable […]
